CRX Trademark

Trademark Overview

On Friday, February 8, 2002, a trademark application was filed for CRX with the United States Patent and Trademark Office. The USPTO has given the CRX trademark a serial number of 78976143. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 2, 2012. This trademark is owned by CombinatoRx, Inc.. The CRX trademark is filed in the Pharmaceutical Products category with the following description:

Prescription pharmaceuticals, namely, therapeutic agents and/or combination therapeutic agents for the treatment of an immunoinflammatory disease

General Information

Serial Number78976143
Word MarkCRX
Filing DateFriday, February 8, 2002
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 2, 2012
Registration Number2980066
Registration DateTuesday, July 26, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 24, 2004

Trademark Statements

Goods and ServicesPrescription pharmaceuticals, namely, therapeutic agents and/or combination therapeutic agents for the treatment of an immunoinflammatory disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 2, 2012
Primary Code005
First Use Anywhere DateMonday, January 31, 2005
First Use In Commerce DateMonday, January 31, 2005

Trademark Owner History

Party NameZALICUS INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02142
Party NameCombinatoRx, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBoston, MA 02118
Party NameCombinatoRx, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02118
Party NameCombinatoRx, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02118

Trademark Events

Event DateEvent Description
Friday, March 2, 2012CANCELLED SEC. 8 (6-YR)
Wednesday, February 16, 2011AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, July 26, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, May 31, 2005LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, May 27, 2005ASSIGNED TO LIE
Wednesday, May 25, 2005ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 25, 2005STATEMENT OF USE PROCESSING COMPLETE
Wednesday, May 18, 2005USE AMENDMENT FILED
Wednesday, May 25, 2005DIVISIONAL PROCESSING COMPLETE
Wednesday, May 18, 2005DIVISIONAL REQUEST RECEIVED
Wednesday, May 25, 2005EXTENSION 2 GRANTED
Wednesday, May 18, 2005EXTENSION 2 FILED
Wednesday, May 18, 2005PAPER RECEIVED
Friday, December 3, 2004EXTENSION 1 GRANTED
Thursday, November 18, 2004EXTENSION 1 FILED
Thursday, November 18, 2004PAPER RECEIVED
Tuesday, October 19, 2004ASSIGNED TO EXAMINER
Tuesday, September 7, 2004ASSIGNED TO EXAMINER
Thursday, May 27, 2004PAPER RECEIVED
Tuesday, May 18, 2004NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 24, 2004PUBLISHED FOR OPPOSITION
Wednesday, February 4, 2004NOTICE OF PUBLICATION
Monday, December 22, 2003APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, December 11, 2003CASE FILE IN TICRS
Wednesday, December 10, 2003JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, December 10, 2003EX PARTE APPEAL-INSTITUTED
Thursday, November 20, 2003PAPER RECEIVED
Wednesday, November 26, 2003EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, May 13, 2003NON-FINAL ACTION E-MAILED
Saturday, December 7, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 4, 2003PREVIOUS ACTION COUNT WITHDRAWN
Wednesday, September 25, 2002ASSIGNED TO EXAMINER
Monday, June 17, 2002NON-FINAL ACTION E-MAILED
Thursday, June 13, 2002ASSIGNED TO EXAMINER

Related Keywords

therapeutic agents immunoinflammatory disease treatment combination pharmaceuticals prescription namely